All our whitepapers

Filter by

Reset filter
March 2, 2023 Whitepaper

Multi-Specific Monoclonal Antibodies – Global Clinical Trial Landscape - Focus On Asia Pacific

Asia Pacific has been the fastest growing region in multi-specific monoclonal antibody trials since 2018, with the re

Download
February 8, 2023 Whitepaper

Phase I Trials Global Clinical Trial Landscape – Focus On Asia Pacific

Asia Pacific has been the fastest growing region in Phase I trials in the last ten years, reaching a share of 58% in

Download
December 16, 2022 Whitepaper

Bispecific Antibodies - CMC Considerations

Bispecific antibodies (bsAbs) are genetically engineered, recombinant antibodies that consist of two distinct binding

Download
December 13, 2022 Whitepaper

State of the Global Biotech Landscape: Where the Opportunities Lie

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth.

Download
December 12, 2022 Whitepaper

Vaccines - Asia Pacific - Clinical trial landscape

Between 2017 and 2021, there were close to 1,400 industry sponsored single country vaccine based clinical trials glob

Download
November 8, 2022 Whitepaper

Non-Clinical Testing Considerations: Drugs vs Devices

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most import

Download
November 8, 2022 Whitepaper

Top Therapeutic Areas APAC-CT LANDSCAPE 2022

The global clinical trial landscape has changed significantly, with the Asia Pacific involved in more than a third of

Download
October 25, 2022 Whitepaper

The China Biotech Landscape – Opportunities in China and the Path to USFDA Approval

Global biopharma companies are looking to capitalize on value creation across different geographic regions through ut

Download
September 26, 2022 Whitepaper

Cell & Gene Therapy

Growth comparison of Asia Pacific, particularly China versus rest of the world between 2017 and 2021, shows China hav

Download
September 23, 2022 Whitepaper

Understanding the benefits of the Analytical Target Profile (ATP)

The 2022 revised version of ICH Q14 describes the ATP as a prospective summary of the performance characteristics des

Download
August 5, 2022 Whitepaper

Immuno-oncology – Asia pacific – clinical Trial landscape

Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs.

Download
August 1, 2022 Whitepaper

Modern Technologies Transforming Clinical Development in the APAC Region

Traditional clinical trial models are outdated and causes multiple issues for patients, trial sites, and sponsors.

Download
June 28, 2022 Whitepaper

The role of real world evidence to support US FDA and TGA registrations

Real world evidence (RWE) can contribute valuable information to new medicine registrations, in particular for diseases that are difficult to assess in randomized clinical trials (RCTs) and for emerging technologies such as gene and cell therapies to help enhance our understanding of such products.

Download
May 26, 2022 Whitepaper

Next Generation Sequencing

NGS profiling improves patient outcomes while also lowering treatment costs and time to diagnosis for cancer patients

Download
May 26, 2022 Whitepaper

Evolution of Clinical Trials in the Asia Pacific Region Compared to the US and the EU5

Over the last five years, the global clinical trial landscape has changed significantly. During the analysis period between 2017-2021

Download
August 19, 2021 Whitepaper

Clinical Development Strategies for Western Biotech Companies in China

China’s evolving regulatory reforms have greatly impacted review and approval timelines, streamlined processes, and expedited the development of innovative drugs.

Download
May 26, 2021 Whitepaper

The Benefits of Asia-Pacific Clinical Trials For Biotechs

There has been a continued shift of innovation from big pharma companies to biotechs, with the latter paving the ways for advancements in the life sciences industry.

Download
August 27, 2019 Whitepaper

Asia: Preferred Destination for Clinical Trials

Asia is the fastest-growing medicines market globally, with China currently the world’s second-largest market after the US, with medicines spending of $137 billion in 2018, up $40 billion from a decade earlier.

Download
August 27, 2019 Whitepaper

Australia: Preferred Destination for Early Phase Clinical Trials

The clinical trials process is complex. It requires substantial investment and skilled human re-sources, and involves risks, not least, the navigation of complex regulatory processes.

Download